Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Warfarin Sodium,Enlicitide Decanoate,Lisinopril
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : Warfarin Sodium,Enlicitide Decanoate,Lisinopril
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : TWi Pharmaceuticals
Deal Size : $38.5 million
Deal Type : Acquisition
Bora Acquires Six US Brand Product Licenses, Rights
Details : Through the acquisition, Bora will utilize Almatica's generic pharmaceutical products, including Zestril (lisinopril), an oral tablet used for treating hypertension, for commercialization purposes.
Product Name : Zestril
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 18, 2023
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : TWi Pharmaceuticals
Deal Size : $38.5 million
Deal Type : Acquisition
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2021
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Zirconium Cyclosilicate,Lisinopril,Valsartan,Irbesartan
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2021
Lead Product(s) : Sodium Zirconium Cyclosilicate,Lisinopril,Valsartan,Irbesartan
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : AZTIQ PHARMA
Deal Size : $350.0 million
Deal Type : Acquisition
Aztiq Buys 17% Stake in Alvogen US
Details : Zestril (lisinopril) belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily. Zestril is used to treat high blood pressure (hypertension) in adults and children who are at least 6 years old.
Product Name : Zestril
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 30, 2021
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : AZTIQ PHARMA
Deal Size : $350.0 million
Deal Type : Acquisition
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Preparation Products of Yiling Pharma Approved by FDA for Launch in the US Market
Details : The announcement showed that Lisinopril Tablets are mainly used for the treatment of essential hypertension (EH) and renal vascular hypertension (RVH) and were originally researched and developed by Astrazeneca and approved for launch in the United State...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2020
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Lupus Research Alliance
Deal Size : Inapplicable
Deal Type : Inapplicable
Centrally Acting ACE Inhibition in SLE
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 24, 2020
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Lupus Research Alliance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Chinese University of Hong Kong
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Bioequivalence Study on Two Lisinopril Tablets 20mg Formulations
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2018
Lead Product(s) : Lisinopril
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Chinese University of Hong Kong
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 08, 2018
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : National Institute of Diabetes and Digestive and Kidney Diseases | Aminu Kano Teaching Hospital | Frederick National Laboratory | Brigham and Women's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2017
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : National Institute of Diabetes and Digestive and Kidney Diseases | Aminu Kano Teaching Hospital | Frederick National Laboratory | Brigham and Women's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable